Monthly information on share capital and company voting rights

Rhea-AI Summary

Cellectis, a clinical-stage biotechnology company, is advancing its gene-editing technology, TALEN®, to develop innovative cell therapies for cancer treatment. As of August 31, 2022, the company reported a total of 45,550,810 shares in capital and 51,615,672 voting rights. With over 22 years of expertise in gene editing, Cellectis focuses on off-the-shelf CAR-T therapies aimed at various blood cancers, including AML and B-ALL. The company is listed on both the Nasdaq Global Market (ticker: CLLS) and Euronext Growth (ticker: ALCLS).

Positive

• Developing innovative CAR-T therapies for blood cancers.
• Over 22 years of expertise in gene editing.
• Focus on unmet medical needs in cancer treatment.

Negative

• None.

(Article 223-16 of General Regulation of the French financial markets authority)

NEW YORK, Sept. 19, 2022 (GLOBE NEWSWIRE) --

Listing market: Euronext Growth

ISIN code: FR0010425595

Date	Total number of shares in the capital	Total number of voting rights
08/31/2022	45,550,810	51,615,672

About Cellectis
Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. Cellectis utilizes an allogeneic approach for CAR-T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to make therapeutic gene editing in hemopoietic stem cells for various diseases. As a clinical-stage biopharmaceutical company with over 22 years of expertise in gene editing, Cellectis is developing life-changing product candidates utilizing TALEN®, its gene editing technology, and PulseAgile, its pioneering electroporation system to harness the power of the immune system in order to treat diseases with unmet medical needs. As part of its commitment to a cure, Cellectis remains dedicated to its goal of providing lifesaving UCART product candidates for multiple cancers including acute myeloid leukemia (AML), B-cell acute lymphoblastic leukemia (B-ALL) and multiple myeloma (MM). .HEAL is a new platform focusing on hemopoietic stem cells to treat blood disorders, immunodeficiencies and lysosomal storage diseases.

Cellectis’ headquarters are in Paris, France, with locations in New York, New York and Raleigh, North Carolina.

Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS).

For more information, visit www.cellectis.com
Follow Cellectis on social media: @cellectis, LinkedIn and YouTube.

For further information, please contact:

Media contacts:
Pascalyne Wilson, Director, Communications, +33776991433, media@cellectis.com
Margaret Gandolfo, Senior Manager, Communications, +1 (646) 628 0300

Investor Relation contact:
Arthur Stril, Chief Business Officer, +1 (347) 809 5980, investors@cellectis.com
Ashley R. Robinson, LifeSci Advisors, +1 (617) 430 7577 

Attachment

• Voting_Rights_PR_August_EN.pdf

FAQ

What is Cellectis doing in the field of gene editing?

Cellectis is developing life-saving CAR-T therapies using its TALEN® gene editing technology to treat various blood cancers.

How many shares and voting rights does Cellectis have as of August 31, 2022?

As of August 31, 2022, Cellectis reported 45,550,810 shares in capital and 51,615,672 voting rights.

What ticker symbols are associated with Cellectis?

Cellectis is listed on the Nasdaq Global Market under the symbol CLLS and on Euronext Growth under the symbol ALCLS.